Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.55 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.49 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909026 | 0.91 | NR4A2 (0.63) | PTGER4PTGER2PPARGEPHX2PPARA | |
| SCHEMBL12999033 | 0.90 | MEN1 (0.53) | PTGER4PTGER2PPARGMEN1KMT2A | |
| SCHEMBL2905853 | 0.88 | NR4A2 (0.62) | PTGER4PTGER2PPARGEPHX2PPARA | |
| SCHEMBL3766516 | 0.84 | RXRA (0.65) | PTGER4PTGER2EPHX2NR4A2RXRA | |
| SCHEMBL2906311 | 0.83 | NR4A2 (0.62) | PTGER4PTGER2PPARGEPHX2NR4A2 | |
| SCHEMBL2909519 | 0.82 | PPARG (0.56) | PTGER4PPARGEPHX2TOP2ARXRA | |
| SCHEMBL2908779 | 0.82 | NR4A2 (0.65) | PTGER4NR4A2MEN1POLBKMT2A | |
| SCHEMBL2907948 | 0.82 | MMP13 (0.62) | PTGER4TOP2ARXRARXRBRXRG | |
| SCHEMBL12999000 | 0.81 | MRGPRX4 (0.56) | PPARANR4A2MEN1POLBKMT2A | |
| SCHEMBL2910612 | 0.79 | RXRA (0.64) | PTGER4PTGER2PPARANR4A2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220029-B1 | Benzamide compounds and their use as prostaglandin E4 receptor agonists | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | claimed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | claimed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | claimed |
| EP-2220029-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | claimed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | claimed |
| EP-2220029-B1 | Benzamide compounds and their use as prostaglandin E4 receptor agonists | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| EP-2220029-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305166-A1 | NOVEL COMPOUNDS | F12, C1R, RPS4X | PTGER4 747/4885PTGER2 1006/4885PPARG 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.